Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
No news for this category today.
----------------------------------------------
** CANCER / ONCOLOGY News **
Data Demonstrate Significant Effect On Tumor-Stroma Interaction With Infinity's Hedgehog Pathway Inhibitor IPI-926
http://www.medicalnewstoday.com/articles/126818.php
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced that preclinical studies of IPI-926, Infinity's oral Hedgehog pathway inhibitor currently in Phase 1 clinical development, demonstrate that the compound significantly down-regulates Hedgehog signaling in tumor stroma, thereby disrupting the communication process between tumor and stroma, ultimately leading to tumor growth inhibition.
Targeting Tumors With B-RAF Mutations: 2 Drugs Are Better Than 1
http://www.medicalnewstoday.com/articles/126769.php
In a proportion of human solid tumors, in particular melanomas (a form of skin cancer that is often resistant to chemotherapy), inappropriate activation of the MEK/ERK signaling pathway as a result of mutations in the B-RAF gene promotes tumor cell growth and survival.
The FDA Approves Production Process Strategy Of Aplidin(R), New Marine-Derived Anti-Tumor Agent, Proposed By PharmaMar
http://www.medicalnewstoday.com/articles/126754.php
The Food and Drug Administration (FDA) has accepted the proposal made by PharmaMar, of the Zeltia Group for the production process of Aplidin®, a new marine-derived anti-tumor agent, in clinical development for the treatment of hematological and solid tumors.
Erbitux Receives CHMP Positive Opinion For 1st-Line Use In Head And Neck Cancer, Europe
http://www.medicalnewstoday.com/articles/126752.php
Merck Serono, a division of Merck KGaA, announced today that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), to extend the use of the targeted therapy Erbitux® (cetuximab) to include 1st-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined With Standard Of Care Chemotherapy
http://www.medicalnewstoday.com/articles/126678.php
SuperGen, Inc. (NASDAQ: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today presented data on MP-470, its lead product candidate, and four additional posters, at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland.
Moffitt Cancer Center Presents The 2nd Biennial Latinos Y El Cancer Educational Symposium - Free Event Will Be In Spanish
http://www.medicalnewstoday.com/articles/126668.php
Moffitt Cancer Center will host the second biennial Latinos y el cancer Educational Symposium November 8 from 9:30 a.m. to 2 p.m. in the <a href="http://www.moffitt.org/site.aspx?spid=36454F19B1044B38808E35ADD1DFF832" target="_blank" rel="nofollow">Vincent A.
Nerviano Medical Sciences Invited By EORTC-NCI-AACR To Present The State-of-the-Art Of Aurora
http://www.medicalnewstoday.com/articles/126645.php
Aurora inhibitors play a key role in cell duplication and are implicated in both the onset and progression of numerous types of tumour. A lecture focusing on Aurora kinase inhibitors will be presented today by Dr.
Proteolix Presents Solid Tumor Clinical Trial Results For Carfilzomib At EORTC-NCI-AACR International Conference
http://www.medicalnewstoday.com/articles/126644.php
Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, presented positive data from a Phase 1 clinical trial of carfilzomib (PR-171) in patients with advanced solid tumors at the 20th EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland.
Positive Preclinical Data Demonstrating Anti-Tumor Activity Of NKTR-105 (PEG-docetaxel) Presented At 20th EORTC-NCI-AACR Conference
http://www.medicalnewstoday.com/articles/126643.php
Nektar Therapeutics (Nasdaq: NKTR) announced that positive preclinical data for NKTR-105 (PEG-docetaxel) was presented at the 2008 EORTC-NCI-AACR (European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research) Symposium on Molecular Targets and Cancer Therapeutics being held in Geneva, Switzerland.
Mount Sinai Medical Group Surgeons Perform Robotic Cystoprostatectomy For Bladder Cancer
http://www.medicalnewstoday.com/articles/126631.php
In 2007, according to the National Cancer Institute, an estimated 67,100 new cases of bladder cancer will be diagnosed in the United States and 13,750 people will die of the disease. For most men suffering from invasive bladder cancer, the most serious kind, treatment typically involves open surgery to remove the bladder as well as the nearby prostate and reconstruction of an ileum conduit or neobladder to divert urine.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
No Link Between Gardasil, Adverse Events, CDC Says
http://www.medicalnewstoday.com/articles/126693.php
<BR /><A href="http://www.cdc.gov/" target=_new>CDC</A> officials on Wednesday said a federal <A href="http://www.cdc.gov/vaccinesafety/vaers/FDA_and_CDC_Statement.htm" target=_new>study</A> of reported deaths and serious adverse effects in girls and women who received <A href="http://www.
----------------------------------------------
** COLORECTAL CANCER News **
EntreMed's ENMD-2076 Demonstrates Tumor Regression In Human Colon Cancer Model
http://www.medicalnewstoday.com/articles/126642.php
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the presentation of preclinical data for its Aurora A/angiogenesis kinase inhibitor, ENMD-2076.
----------------------------------------------
** LUNG CANCER News **
At Former Ohio Uranium-Processing Plant Major Source Of Radon Exposure Overlooked
http://www.medicalnewstoday.com/articles/126792.php
University of Cincinnati (UC) scientists say that a recent scientific study of a now-closed uranium processing plant near Cincinnati has identified a second, potentially more significant source of radon exposure for former workers.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
No news for this category today.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
Ariad Presents Preclinical Data On Deforolimus And Bicalutamide In Androgen-Independent Prostate Cancer
http://www.medicalnewstoday.com/articles/126680.php
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today presented preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with the anti-androgen agent, bicalutamide, in models of prostate cancer.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment